IBT | About IBT

Subpages

IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies.

IBT’s main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called “Live Biotherapeutic Products” for premature infants. The development of IBP-9414 is currently in its final stages.

The portfolio also includes drug candidates, IBP-1016, IBP-1118, and IBP-1122.

IBP-1016 is for the treatment of gastroschisis, a life-threatening and rare condition where the child is born with externalized abdominal organs.

IBP-1118 aims to prevent ROP (retinopathy of prematurity), a leading cause of blindness in premature infants, while IBP-1122 aims to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital acquired infections.

By developing these drugs, IBT has the opportunity to address medical needs where no available treatments currently exist.

This is how IBT was started

Eamonn Connolly, Head of Research at IBT for a number of years, who had conducted research on Lactobacillus reuteri at BioGaia for many years, had noticed an increasing need and interest among doctors around the world in using Lactobacillus reuteri on premature babies. However, BioGaia’s products were not intended for premature babies or as medicines for specific diseases. When Staffan Strömberg, CEO of IBT, started working at BioGaia, he and Eamonn Connolly saw an opportunity to use their many years of experience in the pharmaceutical industry to meet this significant medical need by developing a pharmaceutical orphan drug.
Together with Staffan Strömberg and Eamonn Connolly, BioGaia started operations in 2013 as a subsidiary of BioGaia, namely IBT, which differentiates itself from its parent company BioGaia by focusing entirely on the development of drugs for infants. On March 18, 2016, BioGaia decided to spin off IBT by distributing all of BioGaia’s shares in IBT to BioGaia’s shareholders. On March 29, 2016, IBT’s Series B shares were admitted to trading on Nasdaq First North.